Mei-Jung Lai

View Scopus Profile

h-index

Research activity per year

Education

2010 臺北醫學大學藥學系博士
2006 University of Sourhern CaliforniaPharmaceutical Sciences 碩士
2001 臺北醫學大學藥學系學士

Experience

2019.12- 臺北醫學大學生技醫療產業研發博士學程副研究員
2019.02- 臺北醫學大學生技醫藥商品化中心副研究員
2018.04-2019.01 臺北醫學大學生技醫藥商品化中心助理研究員
2016.11-2018.03 臺北醫學大學癌症轉譯研究中心助理研究員
2014.08-2016.10 臺北醫學大學轉譯醫學研究中心助理研究員
2013.01-2014.07 臺北醫學大學博士後研究員
2012.03-2012.10 食品藥物管理局審查員
2010.08-2012.02 臺北醫學大學博士後研究員

Research Interests

有機合成

Fingerprint

Dive into the research topics where Mei-Jung Lai is active. These topic labels come from the works of this person. Together they form a unique fingerprint.

1 Similar Profiles

1 Active
5 Finished

Integration of the Lung-On-A-Chip System to Establish a Physiologically Based Pharmacokinetic Model for Advancing the Development of Inhaled Small Interfering Rna Dosage Forms
Lai, M.-J. (PI)
8/1/24 → 7/31/25
Project: A - Government Institution › b - National Science and Technology Council
合成可雙重抑制組織蛋白去乙醯酶6與熱休克蛋白90，並同時調節PD-L1之雜環類抗癌化合物
Lai, M.-J. (PI)
8/1/20 → 7/1/21
Project: A - Government Institution › b - National Science and Technology Council
組蛋白去乙醯酶在血管認知功能損傷中的作用-組蛋白去乙醯酶調節者在血管認知損傷動物可作為新的治療
Lai, M.-J. (PI)
1/1/19 → 12/1/19
Project: A - Government Institution › d - Ministry of Education
Design and Synthesis of Biaryl and Biphenylamino Sulfonamides as Novel Anticancer Agents
Lai, M.-J. (PI)
8/1/16 → 7/31/17
Project: A - Government Institution › b - National Science and Technology Council
TMU103-AE1-B09
Lai, M.-J. (PI)
11/1/14 → 10/31/16
Project: B - Project of TMU › g - Research Grants for Newly Hired Faculty

52 Article
4 Comment/debate

Repurposing Linezolid in Conjunction with Histone Deacetylase Inhibitor Access in the Realm of Glioblastoma Therapies
Chen, I. C., Lin, H. Y., Liu, Z. Y., Cheng, W. J., Yeh, T. Y., Yang, W. B., Tran, H. Y., Lai, M. J., Wang, C. H., Kao, T. Y., Hung, C. Y., Huang, Y. L., Liou, K. C., Hsieh, C. M., Hsu, T. I. & Liou, J. P., 2025, In: Journal of Medicinal Chemistry. 68, 3, p. 2779-2803 25 p.
Research output: Contribution to journal › Article › peer-review

Open Access
Design, synthesis, and biological evaluation of adenosine derivatives targeting DOT1L and HAT as anti-leukemia agents
Sethy, B., Yu, Z. Y., Narwanti, I., Upadhyay, R., Lai, M. J., Lee, S. B. & Liou, J. P., Dec 2024, In: Bioorganic Chemistry. 153, 107771.
Research output: Contribution to journal › Article › peer-review
Dual inhibition of CYP17A1 and HDAC6 by abiraterone-installed hydroxamic acid overcomes temozolomide resistance in glioblastoma through inducing DNA damage and oxidative stress
Sharma, R., Chiang, Y. H., Chen, H. C., Lin, H. Y., Yang, W. B., Nepali, K., Lai, M. J., Chen, K. Y., Liou, J. P. & Hsu, T. I., Apr 1 2024, In: Cancer Letters. 586, 216666.
Research output: Contribution to journal › Article › peer-review
6 Citations (Scopus)
First-in-Class Dual EZH2-HSP90 Inhibitor Eliciting Striking Antiglioblastoma Activity In Vitro and In Vivo
Sharma, S., Wang, S. A., Yang, W. B., Lin, H. Y., Lai, M. J., Chen, H. C., Kao, T. Y., Hsu, F. L., Nepali, K., Hsu, T. I. & Liou, J. P., Feb 22 2024, In: Journal of Medicinal Chemistry. 67, 4, p. 2963-2985 23 p.
Research output: Contribution to journal › Article › peer-review

Open Access
4 Citations (Scopus)
HSP90/LSD1 dual inhibitors against prostate cancer as well as patient-derived colorectal organoids
Tang, D. W., Chen, I. C., Chou, P. Y., Lai, M. J., Liu, Z. Y., Tsai, K. K., Cheng, L. H., Zhao, J. X., Cho, E. C., Chang, H. H., Lin, T. E., Hsu, K. C., Chen, M. C. & Liou, J. P., Nov 15 2024, In: European Journal of Medicinal Chemistry. 278, p. 116801 116801.
Research output: Contribution to journal › Article › peer-review
1 Citation (Scopus)

Combination treatment strategy for pancreatic cancer involving the novel HDAC inhibitor MPT0E028 with a MEK inhibitor beyond K-Ras status
Chao, M.-W. (Contributor), Chang, L.-H. (Contributor), Tu, H.-J. (Contributor), Chang, C.-D. (Contributor), Lai, M.-J. (Contributor), Chen, Y.-Y. (Creator), Liou, J.-P. (Creator), Teng, C.-M. (Contributor) & Pan, S.-L. (Contributor), Figshare, 2019
DOI: 10.6084/m9.figshare.c.4522856.v1, https://springernature.figshare.com/collections/Combination_treatment_strategy_for_pancreatic_cancer_involving_the_novel_HDAC_inhibitor_MPT0E028_with_a_MEK_inhibitor_beyond_K-Ras_status/4522856/1
Dataset
Additional file 4: of Combination treatment strategy for pancreatic cancer involving the novel HDAC inhibitor MPT0E028 with a MEK inhibitor beyond K-Ras status
Chao, M.-W. (Contributor), Chang, L.-H. (Contributor), Tu, H.-J. (Contributor), Chang, C.-D. (Contributor), Lai, M.-J. (Contributor), Chen, Y.-Y. (Creator), Liou, J.-P. (Creator), Teng, C.-M. (Contributor) & Pan, S.-L. (Contributor), Figshare, 2019
DOI: 10.6084/m9.figshare.8202896.v1, https://springernature.figshare.com/articles/Additional_file_4_of_Combination_treatment_strategy_for_pancreatic_cancer_involving_the_novel_HDAC_inhibitor_MPT0E028_with_a_MEK_inhibitor_beyond_K-Ras_status/8202896/1
Dataset
Additional file 5: of Combination treatment strategy for pancreatic cancer involving the novel HDAC inhibitor MPT0E028 with a MEK inhibitor beyond K-Ras status
Chang, L.-H. (Contributor), Liou, J.-P. (Creator), Lai, M.-J. (Contributor), Chang, C.-D. (Contributor), Tu, H.-J. (Contributor), Chao, M.-W. (Contributor), Pan, S.-L. (Contributor), Chen, Y.-Y. (Creator) & Teng, C.-M. (Contributor), Figshare, 2019
DOI: 10.6084/m9.figshare.8202902.v1, https://doi.org/10.6084%2Fm9.figshare.8202902.v1
Dataset
Additional file 3: of Combination treatment strategy for pancreatic cancer involving the novel HDAC inhibitor MPT0E028 with a MEK inhibitor beyond K-Ras status
Chao, M.-W. (Contributor), Chang, L.-H. (Contributor), Tu, H.-J. (Contributor), Chang, C.-D. (Contributor), Lai, M.-J. (Contributor), Chen, Y.-Y. (Creator), Liou, J.-P. (Creator), Teng, C.-M. (Contributor) & Pan, S.-L. (Contributor), Figshare, 2019
DOI: 10.6084/m9.figshare.8202890.v1, https://springernature.figshare.com/articles/Additional_file_3_of_Combination_treatment_strategy_for_pancreatic_cancer_involving_the_novel_HDAC_inhibitor_MPT0E028_with_a_MEK_inhibitor_beyond_K-Ras_status/8202890/1
Dataset
Additional file 2: of Combination treatment strategy for pancreatic cancer involving the novel HDAC inhibitor MPT0E028 with a MEK inhibitor beyond K-Ras status
Chao, M.-W. (Contributor), Chang, L.-H. (Contributor), Tu, H.-J. (Contributor), Chang, C.-D. (Contributor), Lai, M.-J. (Contributor), Chen, Y.-Y. (Creator), Liou, J.-P. (Creator), Teng, C.-M. (Contributor) & Pan, S.-L. (Contributor), Figshare, 2019
DOI: 10.6084/m9.figshare.8202887.v1, https://springernature.figshare.com/articles/Additional_file_2_of_Combination_treatment_strategy_for_pancreatic_cancer_involving_the_novel_HDAC_inhibitor_MPT0E028_with_a_MEK_inhibitor_beyond_K-Ras_status/8202887/1
Dataset

Mei-Jung Lai

Personal profile

Education

Experience

Research Interests

Fingerprint

Collaborations and top research areas from the last five years

Dive into details

Integration of the Lung-On-A-Chip System to Establish a Physiologically Based Pharmacokinetic Model for Advancing the Development of Inhaled Small Interfering Rna Dosage Forms

合成可雙重抑制組織蛋白去乙醯酶6與熱休克蛋白90，並同時調節PD-L1之雜環類抗癌化合物

組蛋白去乙醯酶在血管認知功能損傷中的作用-組蛋白去乙醯酶調節者在血管認知損傷動物可作為新的治療

Design and Synthesis of Biaryl and Biphenylamino Sulfonamides as Novel Anticancer Agents

TMU103-AE1-B09

Repurposing Linezolid in Conjunction with Histone Deacetylase Inhibitor Access in the Realm of Glioblastoma Therapies

Design, synthesis, and biological evaluation of adenosine derivatives targeting DOT1L and HAT as anti-leukemia agents

Dual inhibition of CYP17A1 and HDAC6 by abiraterone-installed hydroxamic acid overcomes temozolomide resistance in glioblastoma through inducing DNA damage and oxidative stress

First-in-Class Dual EZH2-HSP90 Inhibitor Eliciting Striking Antiglioblastoma Activity In Vitro and In Vivo

HSP90/LSD1 dual inhibitors against prostate cancer as well as patient-derived colorectal organoids

Combination treatment strategy for pancreatic cancer involving the novel HDAC inhibitor MPT0E028 with a MEK inhibitor beyond K-Ras status

Additional file 4: of Combination treatment strategy for pancreatic cancer involving the novel HDAC inhibitor MPT0E028 with a MEK inhibitor beyond K-Ras status

Additional file 5: of Combination treatment strategy for pancreatic cancer involving the novel HDAC inhibitor MPT0E028 with a MEK inhibitor beyond K-Ras status

Additional file 3: of Combination treatment strategy for pancreatic cancer involving the novel HDAC inhibitor MPT0E028 with a MEK inhibitor beyond K-Ras status

Additional file 2: of Combination treatment strategy for pancreatic cancer involving the novel HDAC inhibitor MPT0E028 with a MEK inhibitor beyond K-Ras status

Mei-Jung Lai

Personal profile

Education

Experience

Research Interests

Fingerprint

Collaborations and top research areas from the last five years

Projects

Research output

Datasets